The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine

Journal of Infection and Public Health

Volumn 9, Issue 4, 2016, Pages 389-395

  Stasi, Cristina ^a,b   Silvestri, Caterina ^a   Voller, Fabio ^a   Cipriani, Francesco ^a  

^a Health Agency of Tuscany Region   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Acute viral hepatitis; Chronic liver disease; Epidemiology; Hepatitis B virus; Hepatitis C virus

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B VACCINE;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; EPIDEMIOLOGICAL DATA; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; INDUSTRIALIZATION; INFECTION PREVENTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MASS SCREENING; NONHUMAN; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; WORLD HEALTH ORGANIZATION; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; IMMUNOLOGY; INCIDENCE;

ANTIVIRAL AGENTS; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; WORLD HEALTH ORGANIZATION;

EID: 84934777081     PISSN: 18760341     EISSN: 1876035X     Source Type: Journal    
DOI: 10.1016/j.jiph.2015.05.004     Document Type: Review

References (34)

1. World Health Organization. Resolutions. WHA63.18. Available: [accessed 22.09.10]. http://apps.who.int/gb/ebwha/pdf_files/WHA63-REC1/WHA63_REC1-en.pdf.
2. World Health Organization Guidelines for the screening care and treatment of persons with hepatitis C infection 2014, Available: http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755_eng.pdf?.ua=1&ua=1 [accessed April 2014].
3. World Health Organization, 2002. Available: . http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index4.html.
4. Tanaka H., Tsukuma H., Yamano H., Oshima A., Shibata H., Tanaka H., et al. Prospective study on the risk of hepatocellular carcinoma among hepatitis C virus-positive blood donors focusing on demographic factors, alanine aminotransferase level at donation and interaction with hepatitis B virus. Int J Cancer 2004, 112:1075-1080.
5. World Health Organization Data and statistics 2015, Available: http://www.euro.who.int/en/health-topics/communicable-diseases/hepatitis/data-and-statistics.
6. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection, 2015. Available at: . http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf?ua=1.
7. World Health Organization Hepatitis B 2002, Available: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index1.html.
8. Taylor B.C., Yuan J.M., Shamliyan T.A., Shaukat A., Kane R.L., Wilt T.J. Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: a systematic review of evidence. Hepatology 2009, 49:S85-S95.
9. World Health Organization Hepatitis C 2002, Available: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index3.html.
10. World Health Organization Hepatitis B 2002, Available: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index3.html#prevalence.
11. World Health Organization. Fact sheet N204. Updated March 2015. Hepatitis B. Available: . http://www.who.int/mediacentre/factsheets/fs204/en/.
12. Mohd Hanafiah K., Groeger J., Flaxman A.D., Wiersma S.T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013, 57:1333-1342.
13. World Health Organization. Weekly epidemiological record. Available: [accessed 2.10.09]. http://www.who.int/wer/2009/wer8440.pdf.
14. World Health Organization Global health observatory data repository 2014, Available: http://apps.who.int/gho/data/view.main.81300.
15. Mele A., Tosti M.E., Mariano A., Pizzuti R., Ferro A., Borrini B., et al. National surveillance system for acute viral hepatitis (SEIEVA) collaborating group acute hepatitis b 14 years after the implementation of universal vaccination in Italy: areas of improvement and emerging challenges. Clin Infect Dis 2008, 46:868-875.
16. Centre for Disease Prevention and Control (CDC). Guidelines for viral hepatitis surveillance and case management. Available: [accessed 24.05.13]. http://www.cdc.gov/hepatitis/Statistics/SurveillanceGuidelines.htm.
17. Jayasekera C.R., Barry M., Roberts L.R., Nguyen M.H. Treating hepatitis C in lower-income countries. N Engl J Med 2014, 370(May):1869-1871.
18. Toccaceli F., Laghi V., Capurso L., Koch M., Sereno S., Scuderi M. Italian Hepanet Group long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon. J Viral Hepat 2003, 10:126-133.
19. Stasi C., Arena U., Zignego A.L., Corti G., Monti M., Triboli E., et al. Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. Dig Liver Dis 2013, 45:840-843.
20. Tan Z.M., Sun B.C. Effects of antiviral therapy on preventing liver tumorigenesis and hepatocellular carcinoma recurrence. World J Gastroenterol 2013, 19:8895-8901. 10.3748/wjg.v19.i47.8895.
21. Boulière M., Kahloun A., Gascou-Tessonier G. Analogs and fibrosis regression in hepatitis B. Gastroenterol Clin Biol 2009, 33:923-929.
22. Brunetto R.M. A new role for an old marker HBsAg. J Hepatol 2010, 52:475-477.
23. Marcellin P., Bonino F., Yurdaydin C., Hadziyannis S., Moucari R., Kapprell H.-P., et al. B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int 2013, 7:88-97.
24. Janssen H.L., Sonneveld M.J., Brunetto M.R. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?. Gut 2012, 61:641-645. 10.1136/gutjnl-2011-963010.
25. Afdhal N., Everson G., Calleja J.L., McCaughan G., Symonds W.T., Denning J., et al. Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virological response. J Hepatol 2014, 60(Suppl. 1):S28.
26. Hill A., Khoo S., Fortunak J., Simmons B., Ford N. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis 2014, 58:928-936. 10.1093/cid/ciu012.
27. Sofosbuvir (Sovaldi) - Treatment - Hepatitis C Online. Available: . http://www.hepatitisc.uw.edu/page/treatment/drugs/sofosbuvir-drug.
28. Simeprevir (Olysio) - Treatment - Hepatitis C Online. Available: . http://www.hepatitisc.uw.edu/page/treatment/drugs/simeprevir-drug.
29. Pauline Londeix New treatments for hepatitis C virus: strategies for achieving universal access. Medicins du Monde 2014, 8. Available: http://www.hepcoalition.org/IMG/pdf/web_daas_strategies_for_achieving_universal_access_en.pdf [accessed 21.04.14].
30. Gilead offers Egypt new hepatitis C drug at 99 percent discount. Available: [accessed 21.03.14]. http://www.reuters.com/article/2014/03/21/us-hepatitis-egypt-gilead-sciences-idUSBREA2K1VF20140321.
31. Schinazi R., Halfon P., Marcellin P., Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int 2014, 34:69-78.
32. Vallet-Pichard A., Pol S., Hepatitis B virus treatment beyond the guidelines: special populations and consideration of treatment withdrawal. Therap Adv Gastroenterol 2014, 7:148-155.
33. Fung J., Yuen M.F. This is hepatitis - it is closer than you think. Indian J Med Res 2012, 136:3-6.
34. Kapoor R., Kottilil S. Strategies to eliminate HBV infection. Future Virol 2014, 9:565-585.